CTMX PE Ratio & Valuation,Is CTMX Overvalued

CTMX Relative Valuation

CTMX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CTMX is overvalued; if below, it's undervalued.

Historical Valuation

CytomX Therapeutics Inc (CTMX) is now in the Overvalued zone, suggesting that its current forward PS ratio of 21.03 is considered Overvalued compared with the five-year average of 13.15. The fair price of CytomX Therapeutics Inc (CTMX) is between 1.15 to 3.29 according to relative valuation methord. Compared to the current price of 4.17 USD , CytomX Therapeutics Inc is Overvalued By 26.56%.

Relative Value

Fair Zone

1.15-3.29

Current Price：4.17

26.56%

Overvalued

-11.39

-8.60

EV/EBITDA

CytomX Therapeutics Inc. (CTMX) has a current EV/EBITDA of -8.60. The 5-year average EV/EBITDA is -0.61. The thresholds are as follows: Strongly Undervalued below -22.92, Undervalued between -22.92 and -11.76, Fairly Valued between 10.55 and -11.76, Overvalued between 10.55 and 21.71, and Strongly Overvalued above 21.71. The current Forward EV/EBITDA of -8.60 falls within the Historic Trend Line -Fairly Valued range.

-9.89

EV/EBIT

CytomX Therapeutics Inc. (CTMX) has a current EV/EBIT of -9.89. The 5-year average EV/EBIT is -0.19. The thresholds are as follows: Strongly Undervalued below -6.64, Undervalued between -6.64 and -3.42, Fairly Valued between 3.03 and -3.42, Overvalued between 3.03 and 6.26, and Strongly Overvalued above 6.26. The current Forward EV/EBIT of -9.89 falls within the Strongly Undervalued range.

21.03

CytomX Therapeutics Inc. (CTMX) has a current PS of 21.03. The 5-year average PS is 3.57. The thresholds are as follows: Strongly Undervalued below -4.11, Undervalued between -4.11 and -0.27, Fairly Valued between 7.40 and -0.27, Overvalued between 7.40 and 11.24, and Strongly Overvalued above 11.24. The current Forward PS of 21.03 falls within the Strongly Overvalued range.

-11.64

P/OCF

CytomX Therapeutics Inc. (CTMX) has a current P/OCF of -11.64. The 5-year average P/OCF is -4.68. The thresholds are as follows: Strongly Undervalued below -16.58, Undervalued between -16.58 and -10.63, Fairly Valued between 1.28 and -10.63, Overvalued between 1.28 and 7.23, and Strongly Overvalued above 7.23. The current Forward P/OCF of -11.64 falls within the Undervalued range.

-15.39

P/FCF

CytomX Therapeutics Inc. (CTMX) has a current P/FCF of -15.39. The 5-year average P/FCF is -5.86. The thresholds are as follows: Strongly Undervalued below -22.49, Undervalued between -22.49 and -14.18, Fairly Valued between 2.46 and -14.18, Overvalued between 2.46 and 10.78, and Strongly Overvalued above 10.78. The current Forward P/FCF of -15.39 falls within the Undervalued range.

CytomX Therapeutics Inc (CTMX) has a current Price-to-Book (P/B) ratio of 6.45. Compared to its 3-year average P/B ratio of -6.41 , the current P/B ratio is approximately -200.53% higher. Relative to its 5-year average P/B ratio of -32.62, the current P/B ratio is about -119.77% higher. CytomX Therapeutics Inc (CTMX) has a Forward Free Cash Flow (FCF) yield of approximately -10.19%. Compared to its 3-year average FCF yield of -68.63%, the current FCF yield is approximately -85.15% lower. Relative to its 5-year average FCF yield of -64.89% , the current FCF yield is about -84.30% lower.

6.32

P/B

Median3y

-6.41

Median5y

-32.62

-10.19

FCF Yield

Median3y

-68.63

Median5y

-64.89

Competitors Valuation Multiple

The average P/S ratio for CTMX's competitors is 0.00, providing a benchmark for relative valuation. CytomX Therapeutics Inc Corp (CTMX) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of -82.16%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of CTMX increased by 300.97% over the past 1 year. The primary factor behind the change was an increase in P/E Change from 0.87 to 17.16.

The secondary factor is the Revenue Growth, contributed -82.16%to the performance.

Overall, the performance of CTMX in the past 1 year is driven by P/E Change. Which is more unsustainable.

-82.16%

33.43M → 5.96M

Revenue Growth

-1490.56%

17.16 → -238.62

Margin Expansion

1873.69%

0.87 → 17.16

P/E Change

300.97%

1.03 → 4.13

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is CytomX Therapeutics Inc (CTMX) currently overvalued or undervalued?

What is CytomX Therapeutics Inc (CTMX) fair value?

CTMX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of CytomX Therapeutics Inc (CTMX) is between 1.15 to 3.29 according to relative valuation methord.

How does CTMX's valuation metrics compare to the industry average?

What is the current P/B ratio for CytomX Therapeutics Inc (CTMX) as of Dec 16 2025?

As of Dec 16 2025, CytomX Therapeutics Inc (CTMX) has a P/B ratio of 6.45. This indicates that the market values CTMX at 6.45 times its book value.

What is the current FCF Yield for CytomX Therapeutics Inc (CTMX) as of Dec 16 2025?

As of Dec 16 2025, CytomX Therapeutics Inc (CTMX) has a FCF Yield of -10.19%. This means that for every dollar of CytomX Therapeutics Inc’s market capitalization, the company generates -10.19 cents in free cash flow.

What is the current Forward P/E ratio for CytomX Therapeutics Inc (CTMX) as of Dec 16 2025?

As of Dec 16 2025, CytomX Therapeutics Inc (CTMX) has a Forward P/E ratio of -11.63. This means the market is willing to pay $-11.63 for every dollar of CytomX Therapeutics Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for CytomX Therapeutics Inc (CTMX) as of Dec 16 2025?

As of Dec 16 2025, CytomX Therapeutics Inc (CTMX) has a Forward P/S ratio of 21.03. This means the market is valuing CTMX at $21.03 for every dollar of expected revenue over the next 12 months.

CTMX Valuation